- Home
- CYCN vs KTTA Comparison
CYCN vs KTTA Comparison
Compare CYCN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- KTTA
- Stock Information
- Founded
- CYCN 2018
- KTTA 2020
- Country
- CYCN United States
- KTTA United States
- Employees
- CYCN N/A
- KTTA N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- KTTA Health Care
- Exchange
- CYCN Nasdaq
- KTTA Nasdaq
- Market Cap
- CYCN 6.5M
- KTTA 5.5M
- IPO Year
- CYCN N/A
- KTTA 2021
- Fundamental
- Price
- CYCN $3.30
- KTTA $0.69
- Analyst Decision
- CYCN
- KTTA
- Analyst Count
- CYCN 0
- KTTA 0
- Target Price
- CYCN N/A
- KTTA N/A
- AVG Volume (30 Days)
- CYCN 32.1K
- KTTA 136.4K
- Earning Date
- CYCN 08-06-2025
- KTTA 08-12-2025
- Dividend Yield
- CYCN N/A
- KTTA N/A
- EPS Growth
- CYCN N/A
- KTTA N/A
- EPS
- CYCN N/A
- KTTA N/A
- Revenue
- CYCN $2,081,000.00
- KTTA N/A
- Revenue This Year
- CYCN N/A
- KTTA N/A
- Revenue Next Year
- CYCN N/A
- KTTA N/A
- P/E Ratio
- CYCN N/A
- KTTA N/A
- Revenue Growth
- CYCN N/A
- KTTA N/A
- 52 Week Low
- CYCN $1.27
- KTTA $0.67
- 52 Week High
- CYCN $9.47
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- CYCN 53.30
- KTTA 32.71
- Support Level
- CYCN $2.95
- KTTA $0.67
- Resistance Level
- CYCN $3.74
- KTTA $0.77
- Average True Range (ATR)
- CYCN 0.34
- KTTA 0.03
- MACD
- CYCN 0.05
- KTTA 0.01
- Stochastic Oscillator
- CYCN 57.28
- KTTA 22.68
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).